| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Accrued expenses and other current liabilities | 4,955 | -5,304 |
| Net cash used in operating activities | -219,926 | -117,411 |
| Purchase of property and equipment | 0 | 0 |
| Net cash used in investing activities | 0 | 0 |
| Proceeds from stock options exercised | 27,513 | 2,918 |
| Net cash provided by financing activities | 27,513 | 2,918 |
| Effect of exchange rate changes on cash and cash equivalents | 312 | -566 |
| Net change in cash and cash equivalents | -192,101 | -115,059 |
| Cash and cash equivalents at beginning of period | 713,971 | - |
| Cash and cash equivalents at end of period | 521,870 | - |
Immunovant, Inc. (IMVT)
Immunovant, Inc. (IMVT)